Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

BACKGROUND: Epidermal growth factor receptor (EGFR) mutations, including a known exon 19 deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong predictors of the response to EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment in lung adenocarcinoma. However, whether patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jiang-Yong, Yu, Si-Fan, Wang, Shu-Hang, Bai, Hua, Zhao, Jun, An, Tong-Tong, Duan, Jian-Chun, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802875/
https://www.ncbi.nlm.nih.gov/pubmed/27001083
http://dx.doi.org/10.1186/s40880-016-0086-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802875/
https://www.ncbi.nlm.nih.gov/pubmed/27001083
http://dx.doi.org/10.1186/s40880-016-0086-2

Ejemplares similares